

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

---

### SECTION 1: Identification of the substance/mixture and of the company/undertaking

#### 1.1 Product identifier

Trade name : Grazoprevir Formulation

#### 1.2 Relevant identified uses of the substance or mixture and uses advised against

Use of the Sub-stance/Mixture : Pharmaceutical

Recommended restrictions on use : Not applicable

#### 1.3 Details of the supplier of the safety data sheet

Company : MSD  
Kilsheelan  
Clonmel Tipperary, IE

Telephone : 353-51-601000

E-mail address of person responsible for the SDS : EHSDATASTEWARD@msd.com

#### 1.4 Emergency telephone number

+1-908-423-6000

---

### SECTION 2: Hazards identification

#### 2.1 Classification of the substance or mixture

##### Classification (REGULATION (EC) No 1272/2008)

Specific target organ toxicity - repeated exposure, Category 2      H373: May cause damage to organs through prolonged or repeated exposure.

#### 2.2 Label elements

##### Labelling (REGULATION (EC) No 1272/2008)

Hazard pictograms :



Signal word : Warning

Hazard statements : H373 May cause damage to organs through prolonged or repeated exposure.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

Precautionary statements :      **Prevention:**  
P260 Do not breathe dust.  
**Response:**  
P314 Get medical advice/ attention if you feel unwell.

Hazardous components which must be listed on the label:  
Grazoprevir

### 2.3 Other hazards

This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

Ecological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Toxicological information: The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

Dust contact with the eyes can lead to mechanical irritation.  
May form explosive dust-air mixture during processing, handling or other means.

## SECTION 3: Composition/information on ingredients

### 3.2 Mixtures

#### Components

Chemical name	CAS-No. EC-No. Index-No. Registration number	Classification	Concentration (% w/w)
Grazoprevir	1350462-55-3	STOT RE 2; H373 (Liver, Testis)	>= 10 - < 20
Sodium n-dodecyl sulfate	151-21-3 205-788-1	Acute Tox. 4; H302 Skin Irrit. 2; H315 Eye Dam. 1; H318 Aquatic Chronic 3; H412  specific concentra- tion limit Eye Irrit. 2; H319 10 - < 20 % Eye Dam. 1; H318 >= 20 %	>= 1 - < 2,5

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1	Revision Date: 30.09.2023	SDS Number: 443813-00021	Date of last issue: 04.04.2023 Date of first issue: 07.01.2016
----------------	------------------------------	-----------------------------	---

		Acute toxicity estimate Acute oral toxicity: 1.200 mg/kg	
--	--	--	--

For explanation of abbreviations see section 16.

### SECTION 4: First aid measures

#### 4.1 Description of first aid measures

- General advice : In the case of accident or if you feel unwell, seek medical advice immediately.  
When symptoms persist or in all cases of doubt seek medical advice.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- If inhaled : If inhaled, remove to fresh air.  
Get medical attention if symptoms occur.
- In case of skin contact : In case of contact, immediately flush skin with plenty of water.  
Remove contaminated clothing and shoes.  
Get medical attention.  
Wash clothing before reuse.  
Thoroughly clean shoes before reuse.
- In case of eye contact : If in eyes, rinse well with water.  
Get medical attention if irritation develops and persists.
- If swallowed : If swallowed, DO NOT induce vomiting.  
Get medical attention if symptoms occur.  
Rinse mouth thoroughly with water.

#### 4.2 Most important symptoms and effects, both acute and delayed

- Symptoms : Headache  
Gastrointestinal discomfort
- Risks : May cause damage to organs through prolonged or repeated exposure.
- Dust contact with the eyes can lead to mechanical irritation.

#### 4.3 Indication of any immediate medical attention and special treatment needed

- Treatment : Treat symptomatically and supportively.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

### SECTION 5: Firefighting measures

#### 5.1 Extinguishing media

Suitable extinguishing media : Water spray  
Alcohol-resistant foam  
Carbon dioxide (CO<sub>2</sub>)  
Dry chemical

Unsuitable extinguishing media : None known.

#### 5.2 Special hazards arising from the substance or mixture

Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.  
Exposure to combustion products may be a hazard to health.

Hazardous combustion products : Carbon oxides  
Nitrogen oxides (NO<sub>x</sub>)  
Metal oxides  
Chlorine compounds  
Sulphur oxides

#### 5.3 Advice for firefighters

Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.  
Use personal protective equipment.

Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.  
Use water spray to cool unopened containers.  
Remove undamaged containers from fire area if it is safe to do so.  
Evacuate area.

---

### SECTION 6: Accidental release measures

#### 6.1 Personal precautions, protective equipment and emergency procedures

Personal precautions : Use personal protective equipment.  
Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).

#### 6.2 Environmental precautions

Environmental precautions : Avoid release to the environment.  
Prevent further leakage or spillage if safe to do so.  
Retain and dispose of contaminated wash water.  
Local authorities should be advised if significant spillages cannot be contained.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

### 6.3 Methods and material for containment and cleaning up

Methods for cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal.  
Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air).  
Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration.  
Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable.  
Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

### 6.4 Reference to other sections

See sections: 7, 8, 11, 12 and 13.

---

## SECTION 7: Handling and storage

### 7.1 Precautions for safe handling

Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion.  
Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.

Local/Total ventilation : Use only with adequate ventilation.

Advice on safe handling : Do not get on skin or clothing.  
Do not breathe dust.  
Do not swallow.  
Avoid contact with eyes.  
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment  
Minimize dust generation and accumulation.  
Keep container closed when not in use.  
Keep away from heat and sources of ignition.  
Take precautionary measures against static discharges.  
Take care to prevent spills, waste and minimize release to the environment.

Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use.  
The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.

### 7.2 Conditions for safe storage, including any incompatibilities

Requirements for storage areas and containers : Keep in properly labelled containers. Store in accordance with the particular national regulations.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

Advice on common storage : Do not store with the following product types:  
Strong oxidizing agents

### 7.3 Specific end use(s)

Specific use(s) : No data available

## SECTION 8: Exposure controls/personal protection

### 8.1 Control parameters

#### Occupational Exposure Limits

Dust 5 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (respirable dust)  
Basis: FOR-2011-12-06-1358

10 mg/m<sup>3</sup>  
Value type (Form of exposure): TWA (total dust)  
Basis: FOR-2011-12-06-1358

Components	CAS-No.	Value type (Form of exposure)	Control parameters	Basis
Grazoprevir	1350462-55-3	TWA	85 µg/m <sup>3</sup> (OEB 3)	Internal
		Wipe limit	850 µg/100 cm <sup>2</sup>	Internal

#### Derived No Effect Level (DNEL) according to Regulation (EC) No. 1907/2006:

Substance name	End Use	Exposure routes	Potential health effects	Value
Sodium chloride	Workers	Inhalation	Long-term systemic effects	2068,62 mg/m <sup>3</sup>
	Workers	Inhalation	Acute systemic effects	2068,62 mg/m <sup>3</sup>
	Workers	Skin contact	Long-term systemic effects	295,52 mg/kg bw/day
	Workers	Skin contact	Acute systemic effects	295,52 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	443,28 mg/m <sup>3</sup>
	Consumers	Inhalation	Acute systemic effects	443,28 mg/m <sup>3</sup>
	Consumers	Skin contact	Long-term systemic effects	126,65 mg/kg bw/day
	Consumers	Skin contact	Acute systemic effects	126,65 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	126,65 mg/kg bw/day
	Consumers	Ingestion	Acute systemic effects	126,65 mg/kg bw/day

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

Sodium n-dodecyl sulfate	Workers	Inhalation	Long-term systemic effects	285 mg/m <sup>3</sup>
	Workers	Skin contact	Long-term systemic effects	4060 mg/kg bw/day
	Consumers	Inhalation	Long-term systemic effects	85 mg/m <sup>3</sup>
	Consumers	Skin contact	Long-term systemic effects	2440 mg/kg bw/day
	Consumers	Ingestion	Long-term systemic effects	24 mg/kg bw/day

### Predicted No Effect Concentration (PNEC) according to Regulation (EC) No. 1907/2006:

Substance name	Environmental Compartment	Value
Sodium chloride	Fresh water	5 mg/l
	Sewage treatment plant	500 mg/l
	Soil	4,86 mg/kg dry weight (d.w.)
Sodium n-dodecyl sulfate	Fresh water	0,176 mg/l
	Marine water	0,018 mg/l
	Sewage treatment plant	1,35 mg/l
	Fresh water sediment	6,97 mg/kg dry weight (d.w.)
	Marine sediment	0,697 mg/kg dry weight (d.w.)
	Soil	1,29 mg/kg dry weight (d.w.)

## 8.2 Exposure controls

### Engineering measures

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face containment devices).

Minimize open handling.

### Personal protective equipment

- Eye/face protection : Wear safety glasses with side shields or goggles.  
If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.  
Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
- Hand protection
- Material : Chemical-resistant gloves
- Remarks : Consider double gloving.
- Skin and body protection : Work uniform or laboratory coat.  
Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces.

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

Respiratory protection	:	Use appropriate degowning techniques to remove potentially contaminated clothing. If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection. Equipment should conform to NS EN 143
Filter type	:	Particulates type (P)

---

### SECTION 9: Physical and chemical properties

#### 9.1 Information on basic physical and chemical properties

Physical state	:	powder
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flammability (solid, gas)	:	May form explosive dust-air mixture during processing, handling or other means.
Flammability (liquids)	:	No data available
Upper explosion limit / Upper flammability limit	:	No data available
Lower explosion limit / Lower flammability limit	:	No data available
Flash point	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
pH	:	No data available
Viscosity	:	
Viscosity, kinematic	:	Not applicable
Solubility(ies)	:	
Water solubility	:	No data available



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

Partition coefficient: n-octanol/water	:	Not applicable
Vapour pressure	:	Not applicable
Relative density	:	No data available
Density	:	No data available
Relative vapour density	:	Not applicable
Particle characteristics Particle size	:	No data available

### 9.2 Other information

Explosives	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Evaporation rate	:	Not applicable

---

## SECTION 10: Stability and reactivity

### 10.1 Reactivity

Not classified as a reactivity hazard.

### 10.2 Chemical stability

Stable under normal conditions.

### 10.3 Possibility of hazardous reactions

Hazardous reactions	:	May form explosive dust-air mixture during processing, handling or other means. Can react with strong oxidizing agents.
---------------------	---	--

### 10.4 Conditions to avoid

Conditions to avoid	:	Heat, flames and sparks. Avoid dust formation.
---------------------	---	---

### 10.5 Incompatible materials

Materials to avoid	:	Oxidizing agents
--------------------	---	------------------

### 10.6 Hazardous decomposition products

No hazardous decomposition products are known.

---

## SECTION 11: Toxicological information

### 11.1 Information on hazard classes as defined in Regulation (EC) No 1272/2008

Information on likely routes of exposure	:	Inhalation Skin contact
--	---	----------------------------

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

---

Ingestion  
Eye contact

### Acute toxicity

Not classified based on available information.

#### Product:

Acute oral toxicity : Acute toxicity estimate: > 2.000 mg/kg  
Method: Calculation method

#### Components:

##### Grazoprevir:

Acute oral toxicity : LD50 (Rat): > 2.000 mg/kg

##### Sodium n-dodecyl sulfate:

Acute oral toxicity : LD50 (Rat): 1.200 mg/kg  
Method: OECD Test Guideline 401

Acute dermal toxicity : LD50 (Rat): > 2.000 mg/kg  
Method: OECD Test Guideline 402  
Remarks: Based on data from similar materials

### Skin corrosion/irritation

Not classified based on available information.

#### Components:

##### Grazoprevir:

Result : No skin irritation

##### Sodium n-dodecyl sulfate:

Species : Rabbit  
Result : Skin irritation

### Serious eye damage/eye irritation

Not classified based on available information.

#### Components:

##### Grazoprevir:

Species : Bovine cornea  
Result : No eye irritation

##### Sodium n-dodecyl sulfate:

Species : Rabbit  
Method : OECD Test Guideline 405  
Result : Irreversible effects on the eye

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

---

### Respiratory or skin sensitisation

#### Skin sensitisation

Not classified based on available information.

#### Respiratory sensitisation

Not classified based on available information.

#### Components:

##### Grazoprevir:

Test Type : Local lymph node assay (LLNA)  
Exposure routes : Dermal  
Result : Not a skin sensitizer.

##### Sodium n-dodecyl sulfate:

Test Type : Maximisation Test  
Exposure routes : Skin contact  
Species : Guinea pig  
Result : negative  
Remarks : Based on data from similar materials

### Germ cell mutagenicity

Not classified based on available information.

#### Components:

##### Grazoprevir:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Result: negative

Test Type: Chromosome aberration test in vitro  
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test  
Application Route: Oral  
Result: negative

Germ cell mutagenicity- Assessment : Weight of evidence does not support classification as a germ cell mutagen.

##### Sodium n-dodecyl sulfate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)  
Method: OECD Test Guideline 471  
Result: negative

Test Type: In vitro mammalian cell gene mutation test  
Result: negative

Genotoxicity in vivo : Test Type: Rodent dominant lethal test (germ cell) (in vivo)  
Species: Mouse  
Application Route: Ingestion

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

Result: negative

### **Carcinogenicity**

Not classified based on available information.

### **Components:**

#### **Sodium n-dodecyl sulfate:**

Species : Rat  
Application Route : Ingestion  
Exposure time : 2 Years  
Method : OECD Test Guideline 453  
Result : negative  
Remarks : Based on data from similar materials

### **Reproductive toxicity**

Not classified based on available information.

### **Components:**

#### **Grazoprevir:**

Effects on fertility : Test Type: Fertility  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 400 mg/kg body weight  
Result: negative

Test Type: Multi-generation study  
Species: Rat  
Application Route: Oral  
Fertility: NOAEL: 400 mg/kg body weight  
Result: No effects on fertility, No effects on foetal development

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Oral  
Embryo-foetal toxicity: NOAEL: 200 mg/kg body weight  
Result: No effects on foetal development

Test Type: Embryo-foetal development  
Species: Rabbit  
Application Route: Intravenous  
Embryo-foetal toxicity: NOAEL: 100 mg/kg body weight  
Result: No effects on foetal development

#### **Sodium n-dodecyl sulfate:**

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

Effects on fertility : Test Type: Two-generation reproduction toxicity study  
Species: Rat  
Application Route: Ingestion  
Method: OECD Test Guideline 416  
Result: negative  
Remarks: Based on data from similar materials

Effects on foetal development : Test Type: Embryo-foetal development  
Species: Rat  
Application Route: Ingestion  
Result: negative  
Remarks: Based on data from similar materials

### STOT - single exposure

Not classified based on available information.

### STOT - repeated exposure

May cause damage to organs through prolonged or repeated exposure.

### Components:

#### Grazoprevir:

Target Organs : Liver, Testis  
Assessment : May cause damage to organs through prolonged or repeated exposure.

### Repeated dose toxicity

### Components:

#### Grazoprevir:

Species : Rat  
NOAEL : 400 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  
Remarks : No significant adverse effects were reported

Species : Rat  
NOAEL : 400 mg/kg  
Application Route : Oral  
Exposure time : 180 Days  
Remarks : No significant adverse effects were reported

Species : Dog  
NOAEL : 15 mg/kg  
LOAEL : 100 mg/kg  
Application Route : Oral  
Exposure time : 270 Days  
Target Organs : Liver, Blood, Bone marrow, gallbladder, spleen, Testis

Species : Mouse  
NOAEL : 200 mg/kg  
LOAEL : 500 mg/kg

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

---

Application Route : Oral  
Exposure time : 90 Days  
Target Organs : Liver, Kidney, Blood

Species : Dog  
NOAEL : 20 mg/kg  
LOAEL : 600 mg/kg  
Application Route : Oral  
Exposure time : 30 Days  
Target Organs : Blood, Testis

Species : Monkey  
NOAEL : 10 mg/kg  
Exposure time : 8 Days  
Remarks : No significant adverse effects were reported

### **Sodium n-dodecyl sulfate:**

Species : Rat  
NOAEL : 488 mg/kg  
Application Route : Ingestion  
Exposure time : 90 Days  
Remarks : Based on data from similar materials

### **Aspiration toxicity**

Not classified based on available information.

## 11.2 Information on other hazards

### **Endocrine disrupting properties**

#### **Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### **Experience with human exposure**

#### **Components:**

##### **Grazoprevir:**

Ingestion : Symptoms: Headache, Gastrointestinal disturbance

---

## SECTION 12: Ecological information

### 12.1 Toxicity

#### **Components:**

##### **Grazoprevir:**

Toxicity to fish : LC50 (Cyprinodon variegatus (sheepshead minnow)): > 10

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

---

- mg/l  
Exposure time: 96 h  
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 10 mg/l  
Exposure time: 48 h  
Method: OECD Test Guideline 202  
Remarks: No toxicity at the limit of solubility
- LC50 (Americamysis): 8,9 mg/l  
Exposure time: 96 h
- Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 10 mg/l  
Exposure time: 72 hrs  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility
- NOEC (Pseudokirchneriella subcapitata (green algae)): 10 mg/l  
Exposure time: 72 hrs  
Method: OECD Test Guideline 201  
Remarks: No toxicity at the limit of solubility
- Toxicity to microorganisms : EC50 : > 1.000 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- NOEC : 1,3 mg/l  
Exposure time: 3 h  
Test Type: Respiration inhibition  
Method: OECD Test Guideline 209
- Toxicity to fish (Chronic toxicity) : NOEC: 0,98 mg/l  
Exposure time: 32 d  
Species: Pimephales promelas (fathead minnow)  
Method: OECD Test Guideline 210  
Remarks: No toxicity at the limit of solubility
- Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC: 5 mg/l  
Exposure time: 21 d  
Species: Daphnia magna (Water flea)  
Method: OECD Test Guideline 211
- Sodium n-dodecyl sulfate:**
- Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 29 mg/l  
Exposure time: 96 h
- Toxicity to daphnia and other aquatic invertebrates : EC50 (Ceriodaphnia dubia (water flea)): 5,55 mg/l  
Exposure time: 48 h

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

Toxicity to algae/aquatic plants	:	ErC50 (Desmodesmus subspicatus (green algae)): > 120 mg/l Exposure time: 72 h
		NOEC (Desmodesmus subspicatus (green algae)): 30 mg/l Exposure time: 72 h
Toxicity to microorganisms	:	EC50 : 135 mg/l Exposure time: 3 h
Toxicity to fish (Chronic toxicity)	:	NOEC: >= 1,357 mg/l Exposure time: 42 d Species: Pimephales promelas (fathead minnow)
Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)	:	NOEC: 0,88 mg/l Exposure time: 7 d Species: Ceriodaphnia dubia (water flea)

### 12.2 Persistence and degradability

#### Components:

##### **Grazoprevir:**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 66 % Exposure time: 28 d
------------------	---	---

##### **Sodium n-dodecyl sulfate:**

Biodegradability	:	Result: Readily biodegradable. Biodegradation: 95 % Exposure time: 28 d Method: OECD Test Guideline 301B
------------------	---	---

### 12.3 Bioaccumulative potential

#### Components:

##### **Grazoprevir:**

Bioaccumulation	:	Species: Lepomis macrochirus (Bluegill sunfish) Bioconcentration factor (BCF): 7,62
-----------------	---	--

Partition coefficient: n-octanol/water	:	log Pow: 3,72
--	---	---------------

##### **Sodium n-dodecyl sulfate:**

Partition coefficient: n-octanol/water	:	log Pow: 0,83
--	---	---------------

### 12.4 Mobility in soil

#### Components:

##### **Grazoprevir:**

Distribution among environ-	:	log Koc: 4,01
-----------------------------	---	---------------



# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

---

mental compartments

### 12.5 Results of PBT and vPvB assessment

**Product:**

Assessment : This substance/mixture contains no components considered to be either persistent, bioaccumulative and toxic (PBT), or very persistent and very bioaccumulative (vPvB) at levels of 0.1% or higher.

### 12.6 Endocrine disrupting properties

**Product:**

Assessment : The substance/mixture does not contain components considered to have endocrine disrupting properties according to REACH Article 57(f) or Commission Delegated regulation (EU) 2017/2100 or Commission Regulation (EU) 2018/605 at levels of 0.1% or higher.

### 12.7 Other adverse effects

No data available

---

## SECTION 13: Disposal considerations

### 13.1 Waste treatment methods

Product : Dispose of in accordance with local regulations. According to the European Waste Catalogue, Waste Codes are not product specific, but application specific. Waste codes should be assigned by the user, preferably in discussion with the waste disposal authorities. Do not dispose of waste into sewer.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

---

## SECTION 14: Transport information

### 14.1 UN number or ID number

ADN : Not regulated as a dangerous good

ADR : Not regulated as a dangerous good

RID : Not regulated as a dangerous good

IMDG : Not regulated as a dangerous good

IATA : Not regulated as a dangerous good

### 14.2 UN proper shipping name

ADN : Not regulated as a dangerous good

---

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version 4.1      Revision Date: 30.09.2023      SDS Number: 443813-00021      Date of last issue: 04.04.2023  
Date of first issue: 07.01.2016

---

**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

### 14.3 Transport hazard class(es)

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA** : Not regulated as a dangerous good

### 14.4 Packing group

**ADN** : Not regulated as a dangerous good  
**ADR** : Not regulated as a dangerous good  
**RID** : Not regulated as a dangerous good  
**IMDG** : Not regulated as a dangerous good  
**IATA (Cargo)** : Not regulated as a dangerous good  
**IATA (Passenger)** : Not regulated as a dangerous good

### 14.5 Environmental hazards

Not regulated as a dangerous good

### 14.6 Special precautions for user

Not applicable

### 14.7 Maritime transport in bulk according to IMO instruments

Remarks : Not applicable for product as supplied.

---

## SECTION 15: Regulatory information

### 15.1 Safety, health and environmental regulations/legislation specific for the substance or mixture

REACH - Restrictions on the manufacture, placing on the market and use of certain dangerous substances, mixtures and articles (Annex XVII) : Not applicable  
REACH - Candidate List of Substances of Very High Concern for Authorisation (Article 59). : Not applicable  
REACH - List of substances subject to authorisation (Annex XIV) : Not applicable  
Regulation (EC) No 1005/2009 on substances that deplete the ozone layer : Not applicable  
Regulation (EU) 2019/1021 on persistent organic pollutants (recast) : Not applicable  
Regulation (EC) No 649/2012 of the European Parliament and the Council concerning the export and import : Not applicable

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

of dangerous chemicals

Seveso III: Directive 2012/18/EU of the European Parliament and of the Council on the control of major-accident hazards involving dangerous substances.

Not applicable

### Other regulations:

Note the regulation on organization, leadership and participation, chapter 12 on the work of children and young people.

### The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

## 15.2 Chemical safety assessment

A Chemical Safety Assessment has not been carried out.

## SECTION 16: Other information

Other information : Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

### Full text of H-Statements

H302 : Harmful if swallowed.

H315 : Causes skin irritation.

H318 : Causes serious eye damage.

H373 : May cause damage to organs through prolonged or repeated exposure if swallowed.

H412 : Harmful to aquatic life with long lasting effects.

### Full text of other abbreviations

Acute Tox. : Acute toxicity

Aquatic Chronic : Long-term (chronic) aquatic hazard

Eye Dam. : Serious eye damage

Skin Irrit. : Skin irritation

STOT RE : Specific target organ toxicity - repeated exposure

FOR-2011-12-06-1358 : Norway. Occupational Exposure limits

FOR-2011-12-06-1358 / : Long term exposure limit

TWA

ADN - European Agreement concerning the International Carriage of Dangerous Goods by Inland Waterways; ADR - Agreement concerning the International Carriage of Dangerous Goods by Road; AIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CLP - Classification Labelling Packaging Regulation; Regulation (EC) No 1272/2008; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECHA - European Chemicals Agency; EC-Number - European Community number; ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration as-

# SAFETY DATA SHEET

according to Regulation (EC) No. 1907/2006, as amended by  
Commission Regulation (EU) 2020/878



## Grazoprevir Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 04.04.2023
4.1	30.09.2023	443813-00021	Date of first issue: 07.01.2016

sociated with x% growth rate response; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; RID - Regulations concerning the International Carriage of Dangerous Goods by Rail; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; SVHC - Substance of very high concern; TCSI - Taiwan Chemical Substance Inventory; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative

### Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

### Classification of the mixture:

STOT RE 2                      H373

### Classification procedure:

Calculation method

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

NO / EN